Epix contrast agent re-named AngioMark

August 5, 1998

Epix Medical of Cambridge, MA, and Mallinckrodt of St. Louis announced last month that MS-325, an MRI contrast agent under development at Epix, will be sold in the U.S. and Europe by Mallinckrodt under the trade name AngioMark. The drug is currently in

Epix Medical of Cambridge, MA, and Mallinckrodt of St. Louis announced last month that MS-325, an MRI contrast agent under development at Epix, will be sold in the U.S. and Europe by Mallinckrodt under the trade name AngioMark. The drug is currently in clinical trials, and trademark applications are pending. AngioMark will be used with MR angiography for visualization of arteries and veins. Mallinckrodt and Epix hope the agent will improve the diagnosis of atherosclerotic occlusive disease.